Medtronic 2013 Annual Report Download - page 5
Download and view the complete annual report
Please find page 5 of the 2013 Medtronic annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2 -
3 -
4 -
5 -
6 -
7 -
8 -
9 -
10 -
11 -
12 -
13 -
14 -
15 -
16 -
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
 |
 |
75732me_editorial.indd 1 7/1/13 11:03 AM
Dear Shareholder,
As I complete my second year at Medtronic, I continue to be inspired by our Mission and I’m even more excited
about the opportunities ahead of us. We are building a broad-based platform that can address the fundamental
challenges in healthcare, enabling new standards of care for millions of people around the world. Every region
in the world is challenged with continuously improving outcomes for better care, increasing access so more
people get treated, and improving the eciency of healthcare delivery. In developed markets, the primary focus
is on better, higher quality care at reduced costs, while emerging markets are trying to bring vast populations to
accepted standards of care in an aordable fashion.
To address these global opportunities, we are working
to reinvent, redene, and reposition our company as
a healthcare solutions company, grounded in our key
therapy areas and focused on three major imperatives –
New Therapies to continually improve clinical outcomes,
Economic Value to ensure cost eciency across the
continuum of care, and Globalization to increase access
to quality healthcare for patients around the world. In
Fiscal Year 2013 (FY13) we made progress toward all
three of these imperatives.
New Therapies, Economic Value,
and Globalization
Developing innovative, new therapies to improve clinical
outcomes and driving them to standard of care will always
be our central value proposition in the marketplace.
New therapies remain our core strength, and our
transformational eorts for growth will revolve around Medtronic CEO Omar Ishrak pictured with
our products and therapies for patients and physicians. Mary Warren, who received our Resolute
We brought several new therapies to market in FY13 that Integrity drug-eluting stent to treat coronary
artery disease.
had a meaningful impact on patient care, including our Mary Warren lives by the Medtronic Mission. Literally.
Resolute Integrity drug-eluting stent for the treatment At the emergency room with what she thought were minor
of coronary artery disease in Japan, which has a unique symptoms of a urinary tract infection, Mary almost didn’t believe
doctors who told her she was having a cardiac event. As a
diabetes indication in the U.S. We also launched the Advisa Medtronic employee, she knew that if she needed a device, she
MRI pacemaker for the treatment of abnormally slow heart wanted it to come from Medtronic. Doctors implanted a Medtronic
rhythm in the U.S. and Japan; the RestoreSensor SureScan Resolute Integrity drug-eluting stent. After a quick recovery,
Mary has made it her mission to encourage women never to
MRI spinal cord stimulation system for the treatment of ignore their heart attack symptoms.
chronic pain in Europe; and the CD Horizon Solera spinal
implants and surgical instruments to treat a variety of spinal
conditions in the U.S. and other global markets.